Bayer’s High-Stakes Balancing Act: A $2.45 Billion Biotech Bet Meets a $5 Billion Legal Storm

Bayer acquires Perfuse Therapeutics for up to $2.45B to replace fading Eylea sales, while facing a Supreme Court decision on 100,000+ glyphosate lawsuits.

The Leverkusen-based conglomerate is navigating one of its most consequential periods in recent memory, simultaneously placing a massive wager on its ophthalmology pipeline while bracing for a Supreme Court ruling that could reshape its legal landscape. The contrast could hardly be starker — a bold acquisition designed to fill the revenue hole left by a fading blockbuster, set against a litigation burden that is already bleeding billions in cash.

The Perfuse Deal: Filling the Eylea Void

Bayer’s decision to acquire US biotech Perfuse Therapeutics for up to $2.45 billion marks the company’s largest pharma purchase since the AskBio deal in 2020, ending a years-long hiatus from major M&A. The upfront payment is a relatively modest $300 million, with the remaining $2.15 billion contingent on hitting specific development and commercial milestones — a structure that significantly caps the downside risk.

At the heart of the transaction is PER-001, an endothelin receptor antagonist delivered via a bio-erodible implant directly into the eye. The candidate is currently in Phase II trials, targeting glaucoma and diabetic retinopathy, conditions that affect an estimated 226 million people worldwide. Early study results from 2025 demonstrated a meaningful improvement in vision, and a Phase 2b/3 trial is slated to begin in the second half of this year.

The urgency behind the deal is clear. Bayer’s ophthalmology blockbuster Eylea is losing patent protection, with sales already sliding to roughly €3.1 billion in 2025. The company needs a successor, and Perfuse represents its most aggressive attempt to secure one.

Analyst Reaction: Cautious Optimism

The market responded positively, with shares closing at €38.52 on Wednesday, up nearly 1.9%. JPMorgan’s Richard Vosser maintained his “Overweight” rating with a €50 price target, anticipating a modestly positive impact on the stock. Barclays’ Charles Pitman-King echoed the sentiment, keeping an “Overweight” rating and €48 target, describing the deal as a necessary safeguard for the ophthalmology pipeline.

Deutsche Bank Research has been more measured, recently lifting its price target sharply from €23 to €43 while maintaining a “Hold” rating. The bank forecasts organic growth of 3.6%, driven primarily by the agricultural division.

The Legal Cloud: Supreme Court Showdown Looms

While the Perfuse acquisition grabs headlines, a far more consequential event is approaching. On April 27, Monsanto — now part of Bayer — argued before the US Supreme Court in the Durnell case, a proceeding that could determine the fate of more than 100,000 pending glyphosate lawsuits.

The justices debated for nearly 90 minutes over a conflict in federal law: the FIFRA statute prohibits states from imposing their own labeling requirements on pesticides, yet another provision holds that EPA approvals do not constitute binding legal mandates. The court appeared divided, with Justices Roberts, Gorsuch, and Jackson pressing Bayer on whether states could still pursue claims against the company independently of the EPA. According to a JPMorgan analyst, the ruling could have signaling effects for roughly 80% of outstanding cases.

The financial toll is already baked into the numbers. Bayer expects approximately €5 billion in litigation-related cash outflows this year, with rising net debt and negative free cash flow on the horizon.

Q1 Earnings: A Mixed Picture

The quarterly report, due May 12 at 7:30 AM CEST followed by an investor video call in the afternoon, will provide the first hard data on how these competing forces are shaping the business. Currency headwinds have already clipped revenue by 4.2%.

The pharma division remains the bedrock. Xarelto generated €1.2 billion in sales, while Kerendia grew to €450 million. Crop Science, however, posted €4.9 billion — a 5% decline weighed down by weaker fungicide volumes.

For the full year, management is targeting adjusted EBITDA between €9.6 billion and €10.1 billion, with adjusted earnings per share of €4.30 to €4.80. The May report will reveal whether the company is on track to hit those targets.

Cost-Cutting and Cash Flow

Bayer’s restructuring program is making headway against the legal headwinds. Six organizational layers have been eliminated, and management positions reduced by two-thirds. Cumulative savings from 2024 and 2025 stand at €1.5 billion, with a target of €2 billion by the end of 2026.

Despite these efforts, the stock remains well below its highs. At €38.59, shares have rallied roughly 60% from last May’s trough but still sit about 20% below the February peak of €49.17. The relative strength index of 77 suggests the recent recovery rally has pushed the stock into technically overbought territory.

Analysts are penciling in a dividend of €0.11 per share for the full year — a modest payout that reflects the competing demands of investment, litigation, and debt reduction.